Potential Drug Interactions in COVID-19 Patients with Comorbid Diseases
Keywords:
Comorbid, COVID-19, Drug interactions, Polypharmacy
Abstract
The Corona Virus Disease 2019 (COVID-19) is a global pandemic that has persisted for a considerable period, presenting significant challenges in the management of patients with comorbidities. This study, conducted in 2021 at RSUD Jagakarsa, aimed to analyze potential drug interactions among COVID-19 patients. The research was retrospective, involving medical records from 100 patients selected through total sampling. Using the Lexicomp tool, researchers assessed potential interactions based on comprehensive medical records. Results showed a predominantly female patient group (59%), mainly aged 50-59 years (27%). Hypertension was the most frequently encountered comorbidity (49%), with antiviral medications used by 61.80% of patients and antibiotics by 38.20%. Approximately 62% of patients received more than five types of drug therapies (polypharmacy). Based on the severity of the disease, it was found that the predominant drug interactions were moderate (70.98%) and minor (19.42%). The conclusion of this study is the identification of potential drug interactions in COVID-19 patients with comorbidities. COVID-19, Interaksi obat, Komorbid, PolifarmasiReferences
Albertus, A. (2024). Penatalaksanaan Covid-19. Alomedika. https:///www.alomedika.com
Alkautsar, A. (2021). Hubungan Penyakit Komorbid Dengan Tingkat Keparahan Pasien Covid-19. Jurnal Medika Hutama, 3(1), 1488–1494.
Satria, R. M. A., Tutupoho, R. V., & Chalidyanto, D. (2020). Analisis Faktor Risiko Kematian Dengan Penyakit Komorbid Covid-19. Jurnal Keperawatan Silampari, 4(1), 48–55.
Fauzia, N. S. (2021). Faktor Risiko Terjadinya Coronavirus Disease2019 pada Pasien dengan Komorbid Diabetes Melitus. Arteri: Jurnal Ilmu Kesehatan, 2(4), 106–112.
Handayani, D., Hadi, D. R., Isbaniah, F., Burhan, E., & Agustin., H. (2020). Corona Virus Disease 2019. Jurnal Respirologi Indonesia, 40(2), 119–129.
Hodge, C., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., D., B., Back, D., & Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother, 75(12), 3417–3424.
Iloanusi, S., Mgbere, O., Essien, E. J., & Al, E. (2021). Polypharmacy among COVID-19 patients: A systematic review. J Am Pharm Assoc (2003), 61(5), e14–e25.
Kemenkes RI. (2020). Situasi terkini perkembangan Novel Coronavirus (COVID-19) Data dilaporkan sampai 29 Juni 2020’. https://infeksiemerging.kemkes.go.id/downloads/?dl_cat=5&dl_page=3#.X zEGJO cxXIU.
Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Z., J., P., & Gold, H. S. (2020). Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
Illah, M. N. N. (2021). Analisis Pengaruh Komorbid, Usia, dan Jenis Kelamin Terhadap Meningkatnya Angka Kematian pada Masa Pandemi COVID-19. Jurnal Sosial Sains, 1(10), 1228–1233.
P2P, D. J. P. dan pengendalian P. (2020). Pedoman pencegahan dan pengendalian coronavirus disease (Covid-19).
Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M. H., Sarraf, P., & Djalali, M. (2020). Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male, 23(5), 1416–1424.
Rezaee, H., Pourkarim, F., Pourtaghi-Anvarian, S., Entezari-Maleki, T., & Asvadi-Kermani, T., NouriVaskeh, M. (2021). Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacol Res Perspect, 9(1), e00705.
Rohimah, I. N. (2021). Analisis Interaksi Obat Antihiperrtensi Pada Pasien Rawat Inap Di RSUD dr.Sayidiman Magetan. Para Pemikir: Jurnal Ilmiah Farmasi, 10(1).
Shetty, V., Chowta, M. N., Chowta, K. N., Shenoy, A., Kamath, A., & Kamath, P. (2018). Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital. J Aging Res, 5(7).
Shojaei, A., & Salari, P. (2020). COVID-19 and off label use of drugs: an ethical viewpoint. DARU Journal of Pharmaceutical Sciences, 28, 789–797.
Song, Y., Zhang, M., Yin, L., Wang, K., Zhou, Y., Zhou, M., & Lu, Y. (2020). COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents, 56(2), 106080.
WHO. (2020). Descriptive analysis of COVID- COVID - 19-related spontaneous reports from VigiBase :interim results.
Yuniar, Y., Ramadhiani, Rachmah, A., Asyifa, D., Kirana, W., Putri, A., Apriliana, & Sari, W. (2022). Potensi Interaksi Obat Pada Pasien COVID-19 Terkonfirmasi Dengan Komorbid Di Bangsal Ogan RSUP Dr . Mohammad Hoesin Palembang Periode April-Juni 2021. Majalah Farmasetik, 18(1), 43–50.
Zhuo, W., JS, J., Y, L., & Al, E. (2020). Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China. MedRxiv., 4(7).
Alkautsar, A. (2021). Hubungan Penyakit Komorbid Dengan Tingkat Keparahan Pasien Covid-19. Jurnal Medika Hutama, 3(1), 1488–1494.
Satria, R. M. A., Tutupoho, R. V., & Chalidyanto, D. (2020). Analisis Faktor Risiko Kematian Dengan Penyakit Komorbid Covid-19. Jurnal Keperawatan Silampari, 4(1), 48–55.
Fauzia, N. S. (2021). Faktor Risiko Terjadinya Coronavirus Disease2019 pada Pasien dengan Komorbid Diabetes Melitus. Arteri: Jurnal Ilmu Kesehatan, 2(4), 106–112.
Handayani, D., Hadi, D. R., Isbaniah, F., Burhan, E., & Agustin., H. (2020). Corona Virus Disease 2019. Jurnal Respirologi Indonesia, 40(2), 119–129.
Hodge, C., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., D., B., Back, D., & Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother, 75(12), 3417–3424.
Iloanusi, S., Mgbere, O., Essien, E. J., & Al, E. (2021). Polypharmacy among COVID-19 patients: A systematic review. J Am Pharm Assoc (2003), 61(5), e14–e25.
Kemenkes RI. (2020). Situasi terkini perkembangan Novel Coronavirus (COVID-19) Data dilaporkan sampai 29 Juni 2020’. https://infeksiemerging.kemkes.go.id/downloads/?dl_cat=5&dl_page=3#.X zEGJO cxXIU.
Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Z., J., P., & Gold, H. S. (2020). Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
Illah, M. N. N. (2021). Analisis Pengaruh Komorbid, Usia, dan Jenis Kelamin Terhadap Meningkatnya Angka Kematian pada Masa Pandemi COVID-19. Jurnal Sosial Sains, 1(10), 1228–1233.
P2P, D. J. P. dan pengendalian P. (2020). Pedoman pencegahan dan pengendalian coronavirus disease (Covid-19).
Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M. H., Sarraf, P., & Djalali, M. (2020). Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male, 23(5), 1416–1424.
Rezaee, H., Pourkarim, F., Pourtaghi-Anvarian, S., Entezari-Maleki, T., & Asvadi-Kermani, T., NouriVaskeh, M. (2021). Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. Pharmacol Res Perspect, 9(1), e00705.
Rohimah, I. N. (2021). Analisis Interaksi Obat Antihiperrtensi Pada Pasien Rawat Inap Di RSUD dr.Sayidiman Magetan. Para Pemikir: Jurnal Ilmiah Farmasi, 10(1).
Shetty, V., Chowta, M. N., Chowta, K. N., Shenoy, A., Kamath, A., & Kamath, P. (2018). Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital. J Aging Res, 5(7).
Shojaei, A., & Salari, P. (2020). COVID-19 and off label use of drugs: an ethical viewpoint. DARU Journal of Pharmaceutical Sciences, 28, 789–797.
Song, Y., Zhang, M., Yin, L., Wang, K., Zhou, Y., Zhou, M., & Lu, Y. (2020). COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents, 56(2), 106080.
WHO. (2020). Descriptive analysis of COVID- COVID - 19-related spontaneous reports from VigiBase :interim results.
Yuniar, Y., Ramadhiani, Rachmah, A., Asyifa, D., Kirana, W., Putri, A., Apriliana, & Sari, W. (2022). Potensi Interaksi Obat Pada Pasien COVID-19 Terkonfirmasi Dengan Komorbid Di Bangsal Ogan RSUP Dr . Mohammad Hoesin Palembang Periode April-Juni 2021. Majalah Farmasetik, 18(1), 43–50.
Zhuo, W., JS, J., Y, L., & Al, E. (2020). Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China. MedRxiv., 4(7).
Published
2024-08-05
How to Cite
Musnelina, L., Wulandari, A., & Rianty, I. (2024). Potential Drug Interactions in COVID-19 Patients with Comorbid Diseases. Sainstech Farma: Jurnal Ilmu Kefarmasian, 17(2), 45-50. https://doi.org/https://doi.org/10.37277/sfj.v17i2.1981
Section
Articles
